Factory 99% Nootropics 9-Me-Bc Powder CAS 2521-07-5 9-Methyl-9h-Beta-Carboline

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A442
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: 9-Methyl-9h-Beta-Carboline
• CAS: 2521-07-5
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 10g
• Function: Nootropics
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	9-Methyl-9h-Beta-Carboline
Appearance	White Powder
CAS NO.	2521-07-5
Molecular Formula	C13H10N2
Storage	Keep in a cool, dry, dark location

 

 

 

9-Methyl-9H-β-Carboline is an indole alkaloid derived from tryptophan metabolism. It is a heterocyclic compound with a tricyclic structure, featuring a ring fused to two benzene rings.

 

 

1. Pharmaceutical Research: 9-Methyl-9H-β-Carboline has been studied for its potential pharmacological properties, including its ability to act as a non-competitive antagonist at receptors.
2. Biochemical Studies: It serves as a tool in biochemical research to investigate the function and regulation of GABA-A receptors, which are involved in neuronal inhibition and anxiety regulation.
3. Synthetic Chemistry: Due to its unique structure, 9-Methyl-9H-β-Carboline is also used as a starting material or intermediate in the synthesis of other biologically active compounds.

1. GABA-A Receptor Modulation: 9-Methyl-9H-β-Carboline binds to sites on GABA-A receptors, modulating their activity and potentially affecting processes such as sedation, anxiety, and memory.
2. Neuroprotective Effects: Preliminary studies suggest that it may have neuroprotective properties, possibly by reducing oxidative stress or modulating neuroinflammatory responses.
3. Anticonvulsant Activity: Some research indicates that 9-Methyl-9H-β-Carboline or related compounds may exhibit anticonvulsant activity, making them potential candidates for the development of new therapeutic agents for epilepsy and other neurological disorders.